Alaunos Therapeutics Inc [NASDAQ: TCRT] stock went on a downward path that fall over -10.59% on Tuesday, amounting to a one-week price decrease of less than -20.70%. The company report on November 14, 2023 at 7:30 AM that Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives.
Best Response to TCR-T.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients.
Over the last 12 months, TCRT stock dropped by -93.12%. The one-year Alaunos Therapeutics Inc stock forecast points to a potential upside of 99.07. The average equity rating for TCRT stock is currently 3.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $17.88 million, with 240.41 million shares outstanding and 229.29 million shares in the current float. Compared to the average trading volume of 3.13M shares, TCRT stock reached a trading volume of 36760219 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Alaunos Therapeutics Inc [TCRT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TCRT shares is $7.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TCRT stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Alaunos Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 04, 2022.
The Average True Range (ATR) for Alaunos Therapeutics Inc is set at 0.01, with the Price to Sales ratio for TCRT stock in the period of the last 12 months amounting to 6.10. The Price to Book ratio for the last quarter was 1.29, with the Price to Cash per share for the same quarter was set at 0.05.
TCRT Stock Performance Analysis:
Alaunos Therapeutics Inc [TCRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.70. With this latest performance, TCRT shares dropped by -30.50% in over the last four-week period, additionally sinking by -88.02% over the last 6 months – not to mention a drop of -93.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRT stock in for the last two-week period is set at 33.97, with the RSI for the last a single of trading hit 32.01, and the three-weeks RSI is set at 34.17 for Alaunos Therapeutics Inc [TCRT]. The present Moving Average for the last 50 days of trading for this stock 0.1104, while it was recorded at 0.0891 for the last single week of trading, and 0.4008 for the last 200 days.
Insight into Alaunos Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Alaunos Therapeutics Inc [TCRT] shares currently have an operating margin of -1205.95 and a Gross Margin at +5.58. Alaunos Therapeutics Inc’s Net Margin is presently recorded at -1291.24.
Return on Total Capital for TCRT is now -48.44, given the latest momentum, and Return on Invested Capital for the company is -63.11. Return on Equity for this stock declined to -78.11, with Return on Assets sitting at -47.22. When it comes to the capital structure of this company, Alaunos Therapeutics Inc [TCRT] has a Total Debt to Total Equity ratio set at 50.61. Additionally, TCRT Total Debt to Total Capital is recorded at 33.60, with Total Debt to Total Assets ending up at 30.05. Long-Term Debt to Equity for the company is recorded at 5.68, with the Long-Term Debt to Total Capital now at 3.77.
Reflecting on the efficiency of the workforce at the company, Alaunos Therapeutics Inc [TCRT] managed to generate an average of -$1,109,706 per employee. Receivables Turnover for the company is 5.24 with a Total Asset Turnover recorded at a value of 0.04.Alaunos Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.72 and a Current Ratio set at 3.72.
Alaunos Therapeutics Inc [TCRT] Institutonal Ownership Details
The top three institutional holders of TCRT stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in TCRT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in TCRT stock with ownership which is approximately 5.7994%.
